Abstract:Abstract. Investigation of the nucleotide sequence of the HIV-1 LTR showed the presence of four novel short DNA regions which are homologous to the recognition site for the cellular transcription factor AP-1. Four short oligonucleotide hybrids containing these potential AP-1 sites were constructed and used in gel retardation assays and in competition experiments in order to determine the role of the AP-1 protein in the regulation of HIV-1 expression. The breast MDA MB 468 and cervical HeLa tumor cell lines, wh… Show more
“…The AP-1 activity is elevated in 9/12 lung tumors, in 9/14 bladder tumors and in 7/7 head and neck carcinoma tumors as compared to normal human tissue. These results are in good agreement with our previous study (34) and suggest that these new HIV-1 LTR putative AP-1 sites have the same binding effect as nuclear extracts from HeLa and MDA MB 468 tumor cell lines.…”
Section: Introductionsupporting
confidence: 82%
“…This is not surprising since EjAP-1 contains the AP-1 binding consensus from the E 3 promoter (37), while lab and 4ab are highly homologous (71.5%) to the same sequence (34). However, the non- III II I III I III III II II I II III "All tissue specimens were obtained from lung cancer patients.…”
Section: Resultsmentioning
confidence: 99%
“…Four short DNA regions which are putative AP-1 binding sites were identified in the HIV-1 LTR (34). From these four sequences, region 2 shows the highest homology (85.8%) to the AP-1 consensus (5'-TGAGTCA-3') and therefore the corresponding oligonucleotide hybrid 2ab was used in our previous studies to test the affinity of the AP-1 protein in MDA MB 468 and HeLa tumor cells.…”
Section: Resultsmentioning
confidence: 99%
“…DNA oligonucleotides were as described (34). The oligonucleotides were purified as described (34) and the double stranded oligonucleotides were 5' end-labelled using γ 32 Ρ-ΑΤΡ and T4 polynucleotide kinase and end filled using the Klenow fragment of DNA polymerase according to Maniatis et al (36).…”
Section: Preparation Of Double Stranded Oligonucleotidesmentioning
Abstract.We have previously reported the specific binding of nuclear factor AP-1 isolated from human breast MDA MB 468 and HeLa cervical tumor cell lines to oligonucleotides complementary to three newly elucidated sequences within the HIV-1 LTR. These synthesized oligonucleotides, which bear high homology to the AP-1 recognition sequence, were used in the present study in gel retardation assays together with unfractionated nuclear protein extracts from human lung, bladder and head and neck tumors and adjacent normal tissue to study the role of the AP-1 protein in the regulation of HIV-1 expression. We found increased binding of AP-1 to these oligonucleotides in 9/12 lung tumors, 9/14 bladder tumors and 7/7 head and neck tumors as compared to adjacent normal tissues. This confirms previous results obtained when using MDA MB 468 and HeLa nuclear protein extracts. These results indicate that, AP-1 could be contributing to the HIV-1 transcriptional regulation through its interaction with the AP-1 binding sites of HIV-1 LTR.
“…The AP-1 activity is elevated in 9/12 lung tumors, in 9/14 bladder tumors and in 7/7 head and neck carcinoma tumors as compared to normal human tissue. These results are in good agreement with our previous study (34) and suggest that these new HIV-1 LTR putative AP-1 sites have the same binding effect as nuclear extracts from HeLa and MDA MB 468 tumor cell lines.…”
Section: Introductionsupporting
confidence: 82%
“…This is not surprising since EjAP-1 contains the AP-1 binding consensus from the E 3 promoter (37), while lab and 4ab are highly homologous (71.5%) to the same sequence (34). However, the non- III II I III I III III II II I II III "All tissue specimens were obtained from lung cancer patients.…”
Section: Resultsmentioning
confidence: 99%
“…Four short DNA regions which are putative AP-1 binding sites were identified in the HIV-1 LTR (34). From these four sequences, region 2 shows the highest homology (85.8%) to the AP-1 consensus (5'-TGAGTCA-3') and therefore the corresponding oligonucleotide hybrid 2ab was used in our previous studies to test the affinity of the AP-1 protein in MDA MB 468 and HeLa tumor cells.…”
Section: Resultsmentioning
confidence: 99%
“…DNA oligonucleotides were as described (34). The oligonucleotides were purified as described (34) and the double stranded oligonucleotides were 5' end-labelled using γ 32 Ρ-ΑΤΡ and T4 polynucleotide kinase and end filled using the Klenow fragment of DNA polymerase according to Maniatis et al (36).…”
Section: Preparation Of Double Stranded Oligonucleotidesmentioning
Abstract.We have previously reported the specific binding of nuclear factor AP-1 isolated from human breast MDA MB 468 and HeLa cervical tumor cell lines to oligonucleotides complementary to three newly elucidated sequences within the HIV-1 LTR. These synthesized oligonucleotides, which bear high homology to the AP-1 recognition sequence, were used in the present study in gel retardation assays together with unfractionated nuclear protein extracts from human lung, bladder and head and neck tumors and adjacent normal tissue to study the role of the AP-1 protein in the regulation of HIV-1 expression. We found increased binding of AP-1 to these oligonucleotides in 9/12 lung tumors, 9/14 bladder tumors and 7/7 head and neck tumors as compared to adjacent normal tissues. This confirms previous results obtained when using MDA MB 468 and HeLa nuclear protein extracts. These results indicate that, AP-1 could be contributing to the HIV-1 transcriptional regulation through its interaction with the AP-1 binding sites of HIV-1 LTR.
“…The pentanucleotide p53 binding repeats are underlined. SP-1 oligonucleotide was used as a p53-unrelated oligonucleotide competitor (32). Radioactive end labelling was performed using T4 polynucleotide kinase (Boehringer) and [γ- DNA binding assay.…”
Abstract. p53 is the most frequent target for genetic alterations in a wide variety of human cancers. The product of the p53 tumor suppressor gene binds to DNA and activates transcription from promoters containing its consensus binding site. In the accompanying paper we have found that P53 tumor suppressor protein recognizes specifically a transcriptional element within the human H-ras proto oncogene (Spandidos DA, et al, Int J Oncol 7: 1029-1034, 1995. We transfected Saos-2 cells, which arep53-null cells, with plasmids encoding for the wild type (wt) and for one 'hot spot' mutant (mt) of the p53 gene (H 273). Using the resulted nuclear extracts for gel retardation assays, we showed binding of both the wild-type and the mutant form of p53 to the Η-ras DNA. Furthermore, using nuclear extracts from head and neck tumors and from adjacent normal tissues in gel retardation assays, we found binding of both the wildtype and the p53 mutant in the same responsive element of the H-ras oncogene. These experimental results suggest a direct role of p53 in regulation of Η-ras. Identification of cellular proto-oncogenes as mediators of the transcriptional effects of wild-type and mutant forms of p53 gene, will be a step towards a better understanding of the role of oncogenes and onco-suppressor genes in tumor promotion.
HSF1, a conserved heat shock factor, has emerged as a key regulator of mammalian transcription in response to cellular metabolic status and stress. To our knowledge, it is not known whether HSF1 regulates viral transcription, particularly HIV-1 and its latent form. Here we reveal that HSF1 extensively participates in HIV transcription and is critical for HIV latent reactivation. Mode of action studies demonstrated that HSF1 binds to the HIV 5′-LTR to reactivate viral transcription and recruits a family of closely related multi-subunit complexes, including p300 and p-TEFb. And HSF1 recruits p300 for self-acetylation is also a committed step. The knockout of HSF1 impaired HIV transcription, whereas the conditional over-expression of HSF1 improved that. These findings demonstrate that HSF1 positively regulates the transcription of latent HIV, suggesting that it might be an important target for different therapeutic strategies aimed at a cure for HIV/AIDS.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.